Pharmacopeia Inc

Pharmacopeia — Investor Presentation (May 2008)

36 slides from Pharmacopeia's investor presentation, May 19, 2008

  1. Slide 1: Corporate Presentation May 2008

    Discovering excellence, driving clinical successTM Corporate Presentation May 2008

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

  3. Slide 3: Strategy to Maximize Shareholder Value

    Selected Indications Partner Retain candidates at least to clinical validation with the option to continue alone to NDA for selected indications Discovery Preclinical Development Phase 1 Phase 2 Phase 3 Strategy to Maximize Shareholder Value PS433540 Marketed Product SARM CCR1 JAK3

  4. Slide 4: Strong Partnered Portfolio

    Immuno/Inflam JAK3 Undisclosed PS015146 Metabolic Disease PS248288 Inflammation PS873266 Respiratory PS948115 Inflammation PS386113 Oncology PS095760 Psoriasis/RA p38 MAP kinase PS540446 COPD CXCR2 PS291822 NDA Filed 3 2 I Development Optimization Lead Generation Program Clinical Phase Preclinical S

  5. Slide 5: Strategic Alliances With Significant Rights

    Strategic Alliances With Significant Rights Secured $60 million in R&D funding and have opportunity for product rights to build future portfolio Discover and develop candidates to clinical proof of concept – GSK have right to develop and commercialize Develop and commercialize JAK3 Inhibitors for im

  6. Slide 6: Large Medical Need and Market Opportunity

    Hypertension and Diabetic Nephropathy Growing patient population with hypertension and diabetes • 50-60% of patients do not achieve blood pressure goals • Most patients require 2 or more drugs to achieve control • 20-40% of diabetics progress to kidney disease Current treatment of kidney disease uns

  7. Slide 7: PS433540 – First-in-class Novel Angiotensin and Endothelin Receptor Antagonist

    PS433540 – First-in-class PS433540 combines the properties of two marketed product classes – Potential for blood pressure control and kidney protection Efficacy and Compliance advantages for dual mechanism – Selectively blocks Angiotensin (AT1) and Endothelin (ETA) – Potent blood pressure lowering i

  8. Slide 8: Potential Advantages of PS433540

    Potential Advantages of PS433540 ET-1 ET-1 ET-1 A II A II A II One compound with two activities – potential synergy of blocking both receptors – full ARB blockade without full ET blockade – reduces pill burden – potentially better efficacy and compliance

  9. Slide 9: Preclinical Studies

    Preclinical Studies A II (AT1) and ET1 (ETA) – Vasoconstriction – Tissue proliferation/fibrosis – Inflammation Preclinical Results - Hypertension – PS433540 (BMS-456567) potent antihypertensive in predictive rat hypertension models (SHR and DOCA)

  10. Slide 10: Successful Phase 1 Development

    Results from Phase 1 Development Safe and well tolerated to date – 2 weeks oral dosing up to 1000 mg Excellent pharmacokinetic profile – Once-a-day oral dosing – Rapid absorption, 24-hour duration of activity Activity in normal subjects – 250, 500 mg fully blocks angiotensin II – At least as potent

  11. Slide 11: Phase 2 Efficacy Studies in Hypertension

    Phase 2 Efficacy Studies in Hypertension Phase 2a Proof of Concept Study Presented American Society of Hypertension New Orleans May 16 2008 Ph 2a: Proof of Concept – 200mg and 500mg PS433540 vs placebo – 4-weeks dosing – Primary endpoint: 24-hr systolic blood pressure – ~ 100 patients randomized – T

  12. Slide 12: Study Design

    Study Design 24 HR ABPM 24 HR ABPM RANDOMIZATION Screening Placebo PS433540 200 mg PS433540 500 mg 4 weeks Single Blind Placebo 3-4 weeks Mean seated SBP >150 - < 179 mmHg DBP < 110 mmHg Mean daytime SBP >140 - < 179 mmHg DBP < 110 mmHg Endpoints Primary – Mean 24 hr Systolic ABPM Secondary – Mean 2

  13. Slide 13: Blood Pressure Measurement Definitions

    Blood Pressure Measurement Definitions SBP = Systolic blood pressure (highest value) DBP = Diastolic blood pressure (lowest value) Mean 24 HR ABPM – average of all blood-pressure measurements taken every 20 minutes over an entire 24 hour period* Mean seated office – average of 3 seated office blood

  14. Slide 14: Disposition

    Disposition (11) Discontinued DB treatment 108 Available at DB lock 93 Available for ABPM analyses (Efficacy Population) (4) ABPM data incomplete 114 Randomized 234 Enrolled in placebo lead-in N

  15. Slide 15: Reasons for Early Discontinuation

    Reasons for Early Discontinuation PS433540 8 1 1 3 3 Placebo 1 0 0 0 1 200 mg 500 mg 2 Total 2 Non-compliance 0 Protocol violation 0 Adverse Event 0 BP uncontrolled

  16. Slide 16: Baseline Characteristics

    Baseline Characteristics PS433540 94 161 31 173 92 20; (80) 5; (20) 0 0 16; (64) 60 Placebo (N=25) 91 160 31 171 90 29; (83) 3; (9) 2; (6) 1; (3) 20; (57) 59 200 mg (N=35) 500 mg (N=33) 96 DBP (mmHg) 160 SBP (mmHg) 30 BMI (kg/m2) 173 Height (cm) 89 Weight (kg) 26; (79) 6; (18) 0 1; (3) Race {n;(%)}

  17. Slide 17: Change from Baseline Mean 24HR ABPM

    -14.8 -10.1 -9.3 0.3 -12.2 -0.4 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean ∆ (mmHg) 95% CI DBP SBP * Change from Baseline Mean 24HR ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540 * * P < 0.001 vs placebo * *

  18. Slide 18: Change from Baseline Mean Seated Office

    -9.8 -10.5 1.6 -17.3 -16.9 -4.2 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean ∆ (mmHg) 95% CI DBP SBP * Change from Baseline Mean Seated Office Placebo N=24 200 mg N=35 500 mg N=32 PS433540 * * P < 0.001 vs placebo * *

  19. Slide 19: Change from Baseline Mean Daytime ABPM

    -12.5 -10.7 1.0 -17.3 -13.7 1.9 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean ∆ (mmHg) 95% CI DBP SBP Change from Baseline Mean Daytime ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540

  20. Slide 20: Change from Baseline Mean Nighttime ABPM

    -6.8 -9.1 -2.7 -10.7 -14.3 -1.6 Mean ∆ (mmHg) 95% CI DBP SBP Change from Baseline Mean Nighttime ABPM Placebo N=25 200 mg N=35 500 mg N=33 PS433540

  21. Slide 21: Change from Baseline Final 4 Hours of Dosing

    -4.7 -8.6 -8.2 -12.5 0.8 -1.2 Mean ∆ (mmHg) 95% CI DBP SBP Change from Baseline Final 4 Hours of Dosing Placebo N=25 200 mg N=35 500 mg N=33 PS433540

  22. Slide 22: Change from Baseline Final 2 Hours of Dosing

    -4.1 -10.2 -5.5 -14.4 -2.1 -3.0 -20.0 -15.0 -10.0 -5.0 0.0 5.0 Mean ∆ (mmHg) 95% CI DBP SBP Change from Baseline Final 2 Hours of Dosing Placebo N=25 200 mg N=35 500 mg N=33 PS433540

  23. Slide 23: Adverse Events

    Adverse Events 1 (2.7) 2 (5.4) 1 (2.9) Nausea/gastritis PS433540 0 3 (8.8) 3 (8.8) 3 (8.8) 1 (2.9) 1 (2.9) 4 (11.8) 9 (26.5) Placebo (N=34) n (%) 1 (2.7) 1 (2.7) 0 1 (2.7) 1 (2.7) 0 1 (2.7) 7 (18.9) 200 mg (N=37) n (%) 500 mg (N=37) n (%) 0 Eczema 4 (10.8) Respiratory 0 Confusion/anxiety/nervousness

  24. Slide 24: Selected Laboratory Parameters: Liver Functions

    Selected Laboratory Parameters. YGT (U/L) AST (U/L) ALT (U/L) PS433540 31.6 33.5 +3.9 22.6 23.3 +1.9 24.8 27.1 +3 Placebo (N=34) 35.7 36.2 +0.3 23.8 22.4 -1.6 31.8 29.8 -2.4 200 mg (N=37) 500 mg (N=37) 28.0 27.7 +0.7 Baseline Follow-up Mean Change 21.3 19.9 -1.3 Baseline Follow-up Mean Change 24.5 2

  25. Slide 25: Selected Laboratory Parameters: Hematology

    Selected Laboratory Parameters Ht (%) Hb (g/dL) PS433540 43.9 44.7 +0.2 14.4 14.7 +0.1 Placebo (N=34) 43.9 42.2 -1.8 14.3 13.9 -0.5 200 mg (N=37) 500 mg (N=37) 44.8 42.6 -2.2 Baseline Follow-up Mean Change 14.7 14.1 -0.7 Baseline Follow-up Mean Change Hematology

  26. Slide 26: Safety

    Safety 2 Serious Adverse Events – syncope/hyponatremia (placebo) – basal cell carcinoma (placebo lead-in) AE profile similar across treatment groups 3 Discontinuations due to AEs (all placebo) No LFT elevation > 2x ULN – average LFT decrease down Mild decreases in hematologic parameters

  27. Slide 27: Conclusions

    Conclusions PS433540 effectively lowers systolic and diastolic blood pressure in Stage I and II hypertensive patients The magnitude of the treatment effect – appears greater than that of existing mono-therapies – confirms the dual pharmacology of PS433540 PS433540 was safe and well tolerated in this

  28. Slide 28: SARM: Medical Need

    SARM: Medical Need – orally active, non-steroidal small molecule – increases muscle mass and strength – minimal effects on the prostate, gonadotropin levels, hematopoiesis Muscle Selective Androgen Receptor Modulators To treat muscle wasting associated with kidney dialysis, cancer, AIDS, severe burn

  29. Slide 29: Potential Benefits of SARM

    Potential Benefits of SARM Disease & Trauma Aging Scarcopenia Osteoporosis Frailty CNS Cancer cachexia AIDS Severe Burns Surgery End stage renal disease Low libido Depression & mood Potential Indications Effects of Androgens

  30. Slide 30: PS178990: What we know so far

    PS178990: What we know so far Safe and well tolerated in SAD – Single oral dose from 0.003 – 2.0 mg – 0.03 mg is projected human efficacious dose Pharmacokinetic profile in man – Kinetics consistent with once-a-day oral dosing – Rapid absorption, 24-hour duration of activity Preclinical activity – 2

  31. Slide 31: SARM - Development Plans

    SARM - Development Plans Complete technology transfer – 1Q-08 Qualify API – 6 kg available Initiate Multiple Ascending Dose study – 2H-08 Initiate Phase 2 – 1H-09 – Effects on lean body mass, muscle strength and prostate in relatively healthy elderly men – 6 months • lean body mass; functional perfo

  32. Slide 32: Approaching Clinical Development

    Approaching Clinical Development CCR1 program in development – Rheumatoid arthritis – IND submission 1H-09 – Superior clinical profile JAK3 programs in late-stage discovery – Develop topical indications with current focus on psoriasis – Alliance with Wyeth for systemic indications

  33. Slide 33: Financial Summary For the Quarter Ended March 31, 2008

    Financial Summary For the Quarter Ended March 31, 2008 $6.2 million in net revenue $11.7 million in net loss Cash, Cash Equivalents and Marketable Securities $61.5 million as of March 31, 2008 December 31, 2008 ending cash balance expected to be > $55 million Stock Information Shares Outstanding ~ 2

  34. Slide 34: Significant Value Drivers

    Significant Value Drivers Clinical development stage company with 3 programs in Ph 2 Strong internal portfolio – PS433540 program in Phase 2 – SARM program in Phase 1 – CCR1 program in development – JAK3 program in discovery Strong partnered portfolio – 2 partnered programs in Phase 2 • CXCR2 antago

  35. Slide 35: Next Steps 2008 - 2009

    Next Steps 2008 - 2009 2H:08 SARM: Initiate Phase 1 MAD study PS433540: Phase 2a Proof of Concept Study Results 1H:08 1H:09 SARM: Initiate Phase 2 PS433540: 2nd Ph 2 Hypertension Results GSK: $5MM Payment CCR1: Submit IND 2H:09 P38 – BMS Phase 2 RA Study Complete CXCR2 – Schering-Plough Phase 2 COPD

  36. Slide 36: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical successTM Corporate Presentation May 2008

Pharmacopeia — Investor Presentation (May 2008) on 6ix